AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
15 November 2022 - 11:00PM
Business Wire
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic
T-cell immunotherapy company, today announced that Diana Brainard,
M.D., Chief Executive Officer, will participate in a fireside chat
at the Piper Sandler 34th Annual Healthcare Conference in New York
on Tuesday, November 29, 2022, at 12:00 p.m. ET.
A live webcast and archived replay of the fireside chat will be
available on the Investors & Press section of the AlloVir
website at https://ir.allovir.com.
About AlloVir AlloVir is a leading late clinical-stage
cell therapy company with a focus on restoring natural immunity
against life-threatening viral diseases in pediatric and adult
patients with weakened immune systems. The company’s innovative and
proprietary technology platforms leverage off-the-shelf,
allogeneic, single- and multi-virus-specific T cells for patients
with T cell deficiencies who are at risk from the life-threatening
consequences of viral diseases. AlloVir’s technology and
manufacturing process enable the potential for the treatment and
prevention of a spectrum of devastating viruses with each single
allogeneic cell therapy. The company is advancing multiple mid- and
late-stage clinical trials across its product portfolio. For more
information visit www.allovir.com or follow us on Twitter or
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221115005388/en/
Media and Investors: Sonia Choi AlloVir
schoi@allovir.com
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Mar 2024 to Apr 2024
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Apr 2023 to Apr 2024